LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $11.12 Consensus Price Target from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $11.50.

Several equities analysts have issued reports on LFST shares. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays increased their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock. KeyCorp raised their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th.

LifeStance Health Group Trading Up 0.8%

Shares of LifeStance Health Group stock opened at $10.90 on Wednesday. The firm has a 50-day moving average of $9.33 and a 200-day moving average of $7.82. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $11.76. The stock has a market cap of $4.23 billion, a PE ratio of 181.67 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $403.48 million during the quarter, compared to the consensus estimate of $387.46 million. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.LifeStance Health Group’s revenue was up 21.2% on a year-over-year basis. As a group, sell-side analysts forecast that LifeStance Health Group will post 0.12 EPS for the current year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of LifeStance Health Group stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. The trade was a 21.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the transaction, the director owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 7,687,394 shares of company stock worth $63,579,701. Company insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

A number of hedge funds have recently bought and sold shares of LFST. Silversmith Partners I GP LLC purchased a new stake in shares of LifeStance Health Group during the fourth quarter worth about $100,842,000. Vanguard Group Inc. lifted its holdings in shares of LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after purchasing an additional 3,086,506 shares during the last quarter. Jennison Associates LLC raised its position in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after acquiring an additional 1,839,465 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock worth $45,998,000 after purchasing an additional 1,790,694 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.